Marc Pfeffer
Cardiovascular Disease · Boston, MANPI 1598703860
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $146,720 of the $164,776 with a category attached, or 89.0%. It is spread thinly across 11 manufacturers, the largest accounting for just 19.3%. Reporting peaked in 2019 at $63,299 and has fallen 69.8% since, to $19,113 in 2025. Among cardiovascular disease clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 112 payments — averaging $1471.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$32K
- Novo Nordisk$27K
- Astrazeneca AB$22K
- GSK$20K
- Astrazeneca UK Limited$16K
- Boehringer Ingelheim International GmbH$13K
- plus $35K from 5 others
Across 23 payments — averaging $33,989 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis Pharma AG$780K
- Aytu Biopharma, Inc.$2K
What the payments were for
- Consulting fees$146,72089%
- Speaking & faculty fees$7,0024%
- Travel & lodging$9,7756%
- Food & beverage$1,2801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 14 | $31,738 |
| Novo Nordisk | 6 | $26,631 |
| Astrazeneca AB | 12 | $22,250 |
| GSK | 9 | $20,440 |
| Astrazeneca UK Limited | 22 | $16,107 |
| Boehringer Ingelheim International GmbH | 9 | $12,675 |
| Novartis Pharma AG | 15 | $12,386 |
| Jazz Pharmaceuticals Inc. | 7 | $10,096 |
| Amarin Pharma, Inc. | 16 | $6,183 |
| Novo Nordisk AS | 1 | $3,450 |
| Alnylam Pharmaceuticals Inc. | 1 | $2,820 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Victoza$30,081
- FARXIGA$20,000
- JARDIANCE$12,675
- EPANOVA$11,000
- LCZ696D_ENTRESTO_CARDIOVASCULAR$9,553
- LOKELMA$6,500
- Vascepa$5,661
- XYWAV$5,472
- LCZ696B_ENTRESTO_CARDIOVASCULAR$1,620
- LCZ696G_ENTRESTO_CARDIOVASCULAR$798
How this compares
$164,776 in reported general payments places this provider in the 95th percentile of 750 cardiovascular disease providers in Massachusetts.
Other cardiovascular disease in Boston
- Marc SabatineBoston$3.9M
- Elizabeth NabelBoston$2.2M
- Kenneth RosenfieldBoston$1.4M
- James JanuzziBoston$1.1M
- Muthiah VaduganathanBoston$972K
- Joseph LoscalzoBoston$926K
- Sunil KapurBoston$823K
- Paul ZeiBoston$786K
- Paul RidkerBoston$572K
- Ignacio Inglessis-AzuajeBoston$545K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.